Juan F. Granada
@jgranadacrf
CEO - Cardiovascular Research Foundation, New York. Passionate for innovation, equality and inclusiveness.
ID: 1297886288
http://www.crf.org 25-03-2013 06:14:35
1,1K Tweet
3,3K Followers
488 Following
Don’t miss Laura Davidson, MD, for her session, “Innovation at NYV: Orthotopic Transcatheter Tricuspid Valve Replacement.” Cardiovascular Research Foundation #NYValves2024. See the full schedule here: nyvalves2024.crfconferences.com/program-guide?…
🗓️Date: ᴀᴘʀɪʟ 17-19, 2025 🗓️ 🌍ʀɪʏᴀᴅʜ - ꜱᴀᴜᴅɪ ᴀʀᴀʙɪᴀ 🌍 Cardiovascular Research Foundation TCT Conference Juan F. Granada MIЯVΛƬ #IC Wail AlkashkariFSCAI,FPICSوائل القشقرى🇸🇦🇨🇦🇺🇲 Khaled AlShaibi Dr.Khalid Al Faraidyالدكتور خالد الفرائضي Mamas A. Mamas
🚨 This #JACCINT analysis of the PRIME-MR registry demonstrated the prognostic implication ☠️ of residual MR, not #MVG, in those with primary #MR undergoing #TEER! bit.ly/3xU686U #vhdMR Augustin Coisne
🌟 Is this the future of #TV regurgitation treatment? 🔍 Meet TriFlO, a unique device featuring 3 anchors positioned at the #TV commissures and polymer leaflets to adapt to irregular shape orifices. #NYValves2024 📊 👉 tctmd.com/slide/percutan… #InnovationWithPurpose Guido Ascione
🌟 #TEER is the gold standard for MR but has limitations. Enter Tioga: a novel #TMVR approach w/unique anchoring mechanism and adaptable valve prosthesis. Explore the #NYValves2024 presentation from Azeem Latib 📊👉 tctmd.com/slide/tioga-no… #InnovationWithPurpose Guido Ascione
📈Dive into the full #NYValves 2024 presentations here: 🔗 Laza Medical: tctmd.com/slide/ai-power… 🔗ROB’E: tctmd.com/slide/first-hu… #InnovationWithPurpose #CardioX Guido Ascione
💡 Curious about solutions for severe, symptomatic #TR? Discover the Laplace #TTVR system! Designed for procedural simplicity & adaptability, it tackles diverse pathologies. 🔍 #NYValves2024 early data Thomas Waggoner 📊 👉 tctmd.com/slide/early-fe… #InnovationWithPurpose Guido Ascione
🔍 #TEER is a great first-line therapy, but complex anatomies often yield suboptimal outcomes. The Half Moon leaflet augmentation device may offer more predictable performance. 🌟 Pilot study #NYValves2024 Azeem Latib 📊 👉tctmd.com/slide/early-hu… #innovationWithPurpose Guido Ascione
🌟 Introducing the MonarQ System for #TTVR 🏥 Designed for both transfemoral & transjugular delivery, it targets patients w/symptomatic, severe TR at high surgical risk. Early data at #NYValves2024 shows promise. 📊 👉 tctmd.com/slide/monarq-s… #InnovationWithPurpose Guido Ascione
🔍 Is this the future of #TMVR? Discover ValSync, an implant that adjusts w/saline-filled balloons to fit each patient’s unique valvular anatomy. Explore the design and data behind this innovation at #NYValves2024 📊 👉 tctmd.com/slide/anatomic… #InnovationWithPurpose Guido Ascione
CRF announces late-breaking clinical trials for #TCT2024 Cardiovascular Research Foundation ow.ly/ThSU50T8I7U
💡 Simple may be best for #TTVR in patients with severe #TR. Trillium is a streamlined solution with a shorter implantation time and no echo guidance or general anesthesia needed. 🏥 #NYValves2024 📊 👉 tctmd.com/slide/heteroto… Philipp Lurz #InnovationWithPurpose Guido Ascione